Board of Directors

Francesco Bellini, PhD has served as Executive Chairman of our board of directors since December 2007. Until 2001, Dr. Bellini was the Chairman of the board of directors and Chief Executive Officer of BioChem Pharma Inc., a biopharmaceutical company focused on infectious diseases and cancer, which he co-founded in 1986. Dr. Bellini currently serves as Chairman of the board of directors of Ascoli Picchio F.C. 1898 S.p.A., Bellus Health Inc., Domodimonti Srl Società Agricola, FB Health S.p.A., Iniziative Immobiliari Marchigiane Srl, and Picchio International Inc., and previously served as chairman of the board of directors of ViroChem Pharma Inc. From 1997 to June 2014, Dr. Bellini served on the board of directors of Molson Coors Brewing Company Inc. Dr. Bellini received his Bachelor of Science degree in 1972 from Concordia University and his PhD in organic chemistry from the University of New Brunswick in 1977.

Harry Baikowitz, PhD has served as a member of our board of directors since July 2012. Since 2000, Dr. Baikowitz has been president of Baikowitz and Associates, Inc., a consulting firm. He was previously president and chief executive officer of Technitrol-Eco Inc., a testing and forensic laboratory company. Dr. Baikowitz holds a Bachelor of Science in Chemistry from Concordia University and a PhD in Polymer Chemistry from the University of Montreal.

Carlo Bellini has served as a member of our board of directors since April 2009 and has also served as our Director of Corporate Development since September 2014. Mr. Bellini previously served as managing director of Vitus Capital Holdings Ltd., a private U.K. fund, from June 2011 to September 2014. He served as President of Domodimonti Srl, an Italian agricultural company, between April 2009 and June 2011. Prior to 2009, Mr. Bellini worked in different capacities at a variety of funds. Mr. Bellini received his Bachelor of Arts in Finance from McGill University.

Roderick Budd, CPA, CA has served as a member of our board of directors since February 2015. From June 1974 to June 2010, Mr. Budd practiced as a public accountant at Ernst & Young LLP. Mr. Budd currently serves as the chairman of the audit committee of the board of directors of Telesta Therapeutics Inc., a biopharmaceutical company focused on oncology, and Bedrocan Cannabis Corp., a producer of pharmaceutical-grade medicinal cannabis. Mr. Budd also serves as chairman of the board of directors and chairman of the audit committee of the board of directors of Immunotec Inc., a nutritional and wellness products company. Mr. Budd holds a Bachelor of Commerce degree from Concordia University, a graduate diploma in accounting from McGill University and is a CPA, CA in Canada.

Lise Hébert, PhD has served as our President and Chief Executive Officer and as a member of our board of directors since April 2009. Prior to joining our company, Dr. Hébert served as vice president of Corporate Communications at Bellus Health Inc., a biotechnology company, for over 10 years. Dr. Hébert holds a PhD in Experimental Medicine from McGill University, where her research focused on amyloidosis and during which time she also conducted research at New York University Medical School. Dr. Hébert completed her post-doctoral studies at the Lady Davis Research Institute at the Montreal Jewish General Hospital and she is the author of several patents. She currently serves on the Life Sciences Committee of the Fédération des Chambres du Commerce du Québec.

Charles Herington has served as a member of our board of directors since June 2014. Since August 2013, Mr. Herington has been president of global operations and vice chairman of Zumba Fitness, LLC. From 2006 to September 2012, he worked at Avon Products, Inc., a beauty products company, where he became president of emerging and developing markets. Since 2003, Mr. Herington has served on the boards of directors of Molson Coors Brewing Company Inc. and NII Holdings, Inc. Mr. Herington received his Bachelor of Science in Chemical Engineering from Instituto Tecnológico y de Estudios Superiores de Monterrey.

Mr. Lamarre has been president of 2856166 Canada Inc. (Lamarre Consultants), which organizes financing for new and expanding companies. He is executive chairman of Semafo Inc. and chairman of D-Box Technologies Inc., Tele-Québec, Le Devoir, Société de Développement Angus, Centre d’Accueil Marcelle, Therillia Development Company Inc. and Mispro Biotech Services Inc. Mr. Lamarre previously served as chairman of GoviEx Uranium Inc. from January 2011 to December 2011. He is a director of TSO3 Inc., Groupe Delom Inc., Caprion Proteomic Inc. and Argos Therapeutics Inc. He is also a member of the Independent Review Committee of Investor Group Investment Management Ltd. Mr. Lamarre received a Bachelor of Business Administration in Applied Economics from École des Hautes Études Commerciales de Montréal.

Lynne D. Nauss has served as a member of our board of directors since November 2013. From 2001 to December 31, 2011, Ms. Nauss worked at Kinetic Concepts Inc., a global medical technology company, where she ultimately held the position of Executive Vice President and Office of the CEO. She was also an executive at Roche Diagnostics for 19 years and is currently a member of the board of directors of Invictus Medical. Ms. Nauss received her Bachelor of Arts in French from Indiana University. Ms. Nauss is currently retired.

Giovanni Scapagnini, MD, PhD has served as a member of our board of directors since October 2009. Dr. Scapagnini has been an associate professor of Clinical Biochemistry at the University of Molise since 2006, where he researches genetics and cellular stress response and the molecular mechanisms of brain aging and neurodegenerative disorders. He received his PhD in Neurobiology and MD from the University of Catania.

Francesco Bellini, PhD has served as Executive Chairman of our board of directors since December 2007. Until 2001, Dr. Bellini was the Chairman of the board of directors and Chief Executive Officer of BioChem Pharma Inc., a biopharmaceutical company focused on infectious diseases and cancer, which he co-founded in 1986. Dr. Bellini currently serves as Chairman of the board of directors of Ascoli Picchio F.C. 1898 S.p.A., Bellus Health Inc., Domodimonti Srl Società Agricola, FB Health S.p.A., Iniziative Immobiliari Marchigiane Srl, and Picchio International Inc., and previously served as chairman of the board of directors of ViroChem Pharma Inc. From 1997 to June 2014, Dr. Bellini served on the board of directors of Molson Coors Brewing Company Inc. Dr. Bellini received his Bachelor of Science degree in 1972 from Concordia University and his PhD in organic chemistry from the University of New Brunswick in 1977.

Harry Baikowitz, PhD has served as a member of our board of directors since July 2012. Since 2000, Dr. Baikowitz has been president of Baikowitz and Associates, Inc., a consulting firm. He was previously president and chief executive officer of Technitrol-Eco Inc., a testing and forensic laboratory company. Dr. Baikowitz holds a Bachelor of Science in Chemistry from Concordia University and a PhD in Polymer Chemistry from the University of Montreal.

Carlo Bellini has served as a member of our board of directors since April 2009 and has also served as our Director of Corporate Development since September 2014. Mr. Bellini previously served as managing director of Vitus Capital Holdings Ltd., a private U.K. fund, from June 2011 to September 2014. He served as President of Domodimonti Srl, an Italian agricultural company, between April 2009 and June 2011. Prior to 2009, Mr. Bellini worked in different capacities at a variety of funds. Mr. Bellini received his Bachelor of Arts in Finance from McGill University.

Roderick Budd, CPA, CA has served as a member of our board of directors since February 2015. From June 1974 to June 2010, Mr. Budd practiced as a public accountant at Ernst & Young LLP. Mr. Budd currently serves as the chairman of the audit committee of the board of directors of Telesta Therapeutics Inc., a biopharmaceutical company focused on oncology, and Bedrocan Cannabis Corp., a producer of pharmaceutical-grade medicinal cannabis. Mr. Budd also serves as chairman of the board of directors and chairman of the audit committee of the board of directors of Immunotec Inc., a nutritional and wellness products company. Mr. Budd holds a Bachelor of Commerce degree from Concordia University, a graduate diploma in accounting from McGill University and is a CPA, CA in Canada.

Lise Hébert, PhD has served as our President and Chief Executive Officer and as a member of our board of directors since April 2009. Prior to joining our company, Dr. Hébert served as vice president of Corporate Communications at Bellus Health Inc., a biotechnology company, for over 10 years. Dr. Hébert holds a PhD in Experimental Medicine from McGill University, where her research focused on amyloidosis and during which time she also conducted research at New York University Medical School. Dr. Hébert completed her post-doctoral studies at the Lady Davis Research Institute at the Montreal Jewish General Hospital and she is the author of several patents. She currently serves on the Life Sciences Committee of the Fédération des Chambres du Commerce du Québec.

Charles Herington has served as a member of our board of directors since June 2014. Since August 2013, Mr. Herington has been president of global operations and vice chairman of Zumba Fitness, LLC. From 2006 to September 2012, he worked at Avon Products, Inc., a beauty products company, where he became president of emerging and developing markets. Since 2003, Mr. Herington has served on the boards of directors of Molson Coors Brewing Company Inc. and NII Holdings, Inc. Mr. Herington received his Bachelor of Science in Chemical Engineering from Instituto Tecnológico y de Estudios Superiores de Monterrey.

Mr. Lamarre has been president of 2856166 Canada Inc. (Lamarre Consultants), which organizes financing for new and expanding companies. He is executive chairman of Semafo Inc. and chairman of D-Box Technologies Inc., Tele-Québec, Le Devoir, Société de Développement Angus, Centre d’Accueil Marcelle, Therillia Development Company Inc. and Mispro Biotech Services Inc. Mr. Lamarre previously served as chairman of GoviEx Uranium Inc. from January 2011 to December 2011. He is a director of TSO3 Inc., Groupe Delom Inc., Caprion Proteomic Inc. and Argos Therapeutics Inc. He is also a member of the Independent Review Committee of Investor Group Investment Management Ltd. Mr. Lamarre received a Bachelor of Business Administration in Applied Economics from École des Hautes Études Commerciales de Montréal.

Lynne D. Nauss has served as a member of our board of directors since November 2013. From 2001 to December 31, 2011, Ms. Nauss worked at Kinetic Concepts Inc., a global medical technology company, where she ultimately held the position of Executive Vice President and Office of the CEO. She was also an executive at Roche Diagnostics for 19 years and is currently a member of the board of directors of Invictus Medical. Ms. Nauss received her Bachelor of Arts in French from Indiana University. Ms. Nauss is currently retired.

Giovanni Scapagnini, MD, PhD has served as a member of our board of directors since October 2009. Dr. Scapagnini has been an associate professor of Clinical Biochemistry at the University of Molise since 2006, where he researches genetics and cellular stress response and the molecular mechanisms of brain aging and neurodegenerative disorders. He received his PhD in Neurobiology and MD from the University of Catania.